Increased midkine expression correlates with desmoid tumour recurrence: a potential biomarker and therapeutic target

2011 ◽  
Vol 225 (4) ◽  
pp. 574-582 ◽  
Author(s):  
Chiara Colombo ◽  
Chad J Creighton ◽  
Markus P Ghadimi ◽  
Svetlana Bolshakov ◽  
Carla L Warneke ◽  
...  
Keyword(s):  
Therapeutic Target ◽  
Tumour Recurrence ◽  
Desmoid Tumour ◽  
Potential Biomarker

scholarly journals miR-27b Suppresses Endothelial Cell Proliferation and Migration by Targeting Smad7 in Kawasaki Disease

2018 ◽  
Vol 48 (4) ◽  
pp. 1804-1814 ◽  
Author(s):  
Xing Rong ◽  
Donghui Ge ◽  
Danping Shen ◽  
Xianda Chen ◽  
Xuliang Wang ◽  
...  
Keyword(s):  
Endothelial Cell ◽  
Kawasaki Disease ◽  
Therapeutic Target ◽  
Umbilical Vein ◽  
Luciferase Reporter ◽  
Endothelial Cell Proliferation ◽  
Cell Functions ◽  
Potential Biomarker ◽  
And Migration ◽  
Proliferation And Migration

Background/Aims: Increasing evidence indicates that microRNAs (miRNAs) play important roles in Kawasaki disease (KD). Our previous study demonstrated that hsa-miR-27b-3p (miR-27b) was up-regulated in KD serum. However, the specific role of miR-27b in KD remains unclear. We aimed to investigate that miR-27b could be a biomarker and therapeutic target for KD treatment. As well, the specific mechanism of miR-27b effecting endothelial cell functions was studied. Methods: The expression of miR-27b and Smad7 was measured by qRT-PCR. Gain-of-function strategy was used to observe the effect of miR-27b on human umbilical vein endothelial cells (HUVECs) proliferation and migration. Bioinformatics analyses were applied to predict miR-27b targets and then we verified Smad7 by a luciferase reporter assay. Western blot was performed to detect the protein expression of Smad7, PCNA, MMP9, MMP12 and TGF-β-related genes. Results: We confirmed that miR-27b was shown to be dramatically up-regulated in KD serum and KD serum-treated HUVECs and that elevated expression of miR-27b suppressed the proliferation and migration of HUVECs. Furthermore, our results verified that miR-27b mediated cell functions by affecting the TGF-β via targeting Smad7 in HUVECs. Conclusion: These results suggested that up-regulated miR-27b had a protective role in HUVECs proliferation and migration via targeting Smad7 and affecting TGF-β pathway. Therefore, miR-27b represented a potential biomarker for KD and may serve as a promising therapeutic target for KD treatment.

DLX6-AS1 is a potential biomarker and therapeutic target in cancer initiation and progression

2021 ◽  
Vol 517 ◽  
pp. 1-8
Author(s):  
Qiuxian Zheng ◽  
Xinyu Gu ◽  
Qin Yang ◽  
Qingfei Chu ◽  
Yiyang Dai ◽  
...  
Keyword(s):  
Therapeutic Target ◽  
Potential Biomarker ◽  
Cancer Initiation

WASF2 Serves as a Potential Biomarker and Therapeutic Target in Ovarian Cancer: A Pan-Cancer Analysis

2021 ◽  
Author(s):  
Xiaofeng Yang ◽  
Yuzhen Ding ◽  
Lu Sun ◽  
Meiting Shi ◽  
Ping Zhang ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Therapeutic Target ◽  
Potential Biomarker ◽  
Pan Cancer

scholarly journals CCT3 acts upstream of YAP and TFCP2 as a potential target and tumour biomarker in liver cancer

2019 ◽  
Vol 10 (9) ◽  
Author(s):  
Ya Liu ◽  
Xiao Zhang ◽  
Jiafei Lin ◽  
Yuxin Chen ◽  
Yongxia Qiao ◽  
...  
Keyword(s):  
Liver Cancer ◽  
Therapeutic Target ◽  
Potential Therapeutic Target ◽  
Liver Malignancy ◽  
Independent Manner ◽  
Diagnostic Biomarkers ◽  
Ubiquitin Protein Ligase ◽  
Promising Therapeutic Target ◽  
Potential Biomarker ◽  
Diagnostic Capacity

Abstract Although Yes-associated protein (YAP) is very important to liver cancer, its nuclear localisation prevents consideration as a promising therapeutic target and a diagnostic biomarker. Recently, we reported that the protumourigenic roles of YAP in liver cancer are indispensable for transcription factor CP2 (TFCP2) in a Hippo-independent manner; however, proteins that act upstream to simultaneously control YAP and TFCP2 remain unclear. The aim of this study was to uncover such proteins and evaluate whether they are potential YAP-associated therapeutic targets and diagnostic biomarkers. Mass spectrometry revealed that chaperonin containing TCP1 subunit 3 (CCT3) co-interact with YAP and TFCP2, and notably, CCT3 is a non-nuclear protein. CCT3 was elevated in liver cancer, and its higher expression was associated with poorer overall survival. Inhibiting CCT3 resulted in a suppressed transformative phenotype in liver cancer cells, suggesting that CCT3 might be a potential therapeutic target. CCT3 prolonged half-life of YAP and TFCP2 by blocking their ubiquitination caused by poly(rC) binding protein 2 (PCBP2) in a beta-transducin repeat containing E3 ubiquitin protein ligase (βTrCP)-independent manner. Interestingly, PCBP2 directly interacted with YAP via a WB motif-WW domain interaction, whereas indirectly interacted with TFCP2 via the aid of YAP. Furthermore, CCT3 was capable of separating PCBP2-YAP interactions, thereby preventing YAP and TFCP2 from PCBP2-induced ubiquitination. Moreover, YAP and TFCP2 were downstream of CCT3 to positively control tumourigenesis, yet such effects were inhibited by PCBP2. Clinically, CCT3 was positively correlated with YAP and TFCP2, and elevated levels of the CCT3-YAP-TFCP2 axis might be critical for liver malignancy. In addition, seral-CCT3 was proven to be a potential biomarker, and its diagnostic capacity was better than that of alpha fetoprotein (AFP) to a certain extent. Together, CCT3 acts as a trigger of YAP and TFCP2 to affect tumourigenesis and serves as a potential therapeutic target and biomarker in liver cancer.

scholarly journals MicroRNA-550a is associated with muscle system conferring poorer survival for esophageal cancer

2019 ◽  
Vol 39 (5) ◽  
Author(s):  
Housong Hong ◽  
Taisheng Liu ◽  
Huazhen Wu ◽  
Jinye Zhang ◽  
Xiaoshun Shi ◽  
...  
Keyword(s):  
Esophageal Cancer ◽  
Survival Time ◽  
Therapeutic Target ◽  
Differential Expression Analysis ◽  
Enrichment Analysis ◽  
Gene Set Enrichment Analysis ◽  
Pathway Enrichment Analysis ◽  
Muscle System ◽  
Expression Levels ◽  
Potential Biomarker

Abstract Background Esophageal cancer (ESCA) is one of the most common cancers in the digestive tract. Approximately 300000 people on an average die of ESCA per year worldwide. The determination of key microRNAs for the prognosis of ESCA is of indispensable significance in the clinical treatment. Methods The differentially expressed microRNAs were screened by analyzing The Cancer Genome Atlas (TCGA) database. By using the survival data of the database, we analyzed correlation between patients’ survival time and miR-550a expression levels. Differential expression analysis and gene set enrichment analysis were performed using the targeted data. Results It was found that patients with high miR-550a expression levels had shorter survival time. Data mining and signal pathway enrichment analysis of TCGA database showed that abnormal miR-550a expressions affected the recurrence of tumors by the muscle system regulation. Conclusions Through the proposed investigation, miR-550a is found to be a potential biomarker as well as non-coding therapeutic target for esophagus cancer. These results suggest that miR-550a may serve as a therapeutic target and predictor for ESCA survival.

scholarly journals Plasma Gelsolin: Indicator of Inflammation and Its Potential as a Diagnostic Tool and Therapeutic Target

2018 ◽  
Vol 19 (9) ◽  
pp. 2516 ◽  
Author(s):  
Ewelina Piktel ◽  
Ilya Levental ◽  
Bonita Durnaś ◽  
Paul Janmey ◽  
Robert Bucki
Keyword(s):  
Therapeutic Target ◽  
Animal Studies ◽  
Recent Progress ◽  
Mechanisms Of Action ◽  
Current Data ◽  
Clinical Use ◽  
Plasma Gelsolin ◽  
Beneficial Effects ◽  
Potential Biomarker ◽  
Efficacy Of Treatment

Gelsolin, an actin-depolymerizing protein expressed both in extracellular fluids and in the cytoplasm of a majority of human cells, has been recently implicated in a variety of both physiological and pathological processes. Its extracellular isoform, called plasma gelsolin (pGSN), is present in blood, cerebrospinal fluid, milk, urine, and other extracellular fluids. This isoform has been recognized as a potential biomarker of inflammatory-associated medical conditions, allowing for the prediction of illness severity, recovery, efficacy of treatment, and clinical outcome. A compelling number of animal studies also demonstrate a broad spectrum of beneficial effects mediated by gelsolin, suggesting therapeutic utility for extracellular recombinant gelsolin. In the review, we summarize the current data related to the potential of pGSN as an inflammatory predictor and therapeutic target, discuss gelsolin-mediated mechanisms of action, and highlight recent progress in the clinical use of pGSN.

Insulinoma-associated protein 1 (INSM1): a potential biomarker and therapeutic target for neuroendocrine tumors

2020 ◽  
Vol 43 (3) ◽  
pp. 367-376
Author(s):  
B. Mahalakshmi ◽  
Rathinasamy Baskaran ◽  
M. Shanmugavadivu ◽  
Ngoc Tuan Nguyen ◽  
Bharath Kumar Velmurugan
Keyword(s):  
Neuroendocrine Tumors ◽  
Therapeutic Target ◽  
Potential Biomarker
Sign in / Sign up

Export Citation Format

Share Document